» Articles » PMID: 16736496

Assessment of Gene Promoter Hypermethylation for Detection of Cervical Neoplasia

Overview
Journal Int J Cancer
Specialty Oncology
Date 2006 Jun 1
PMID 16736496
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Current cervical cancer screening is based on morphological assessment of Pap smears and associated with significant false negative and false positive results. Previously, we have shown that detection of hypermethylated genes in cervical scrapings using quantitative methylation-specific PCR (QMSP) is a promising tool for identification of squamous cell cervical cancer. Aim of the present pilot-study was to evaluate presence of hypermethylated genes in cervical carcinogenesis, both in squamous cell as well as adenocarcinomas. Cervical scrapings were obtained from 30 patients diagnosed with cervical cancer (20 squamous cell carcinomas and 10 adenocarcinomas) and 19 women with histologically normal cervices. The scraped cells were used for determination of promoter hypermethylation by QMSP for 12 genes and for morphological assessment. Overall, CALCA, DAPK, ESR1, TIMP3, APC and RAR-beta2 promoters were significantly more often hypermethylated in cancers than in controls, while adenocarcinomas were more often hypermethylated above the highest control ratio for APC, TIMP3 and RASSF1A promoters. Combining 4 genes (CALCA, DAPK, ESR1 and APC) yielded a sensitivity of 89% (with all adenocarcinomas identified), equal to cytomorphology (89%) and high-risk human papilloma virus (Hr-HPV; 90%). The 4-gene QMSP proved theoretically superior to cytomorphology as well as Hr-HPV in specificity (100% vs. 83 and 68%, respectively), because cytology identified 3 controls as moderate or severe dyskaryosis and 6 controls were positive for Hr-HPV. In conclusions, QMSP of 4 gene promoters combined appears to have comparable sensitivity and potentially better specificity in comparison to "classic" cytomorphological assessment and Hr-HPV detection. QMSP holds promise as a new diagnostic tool for both squamous cell carcinoma and adenocarcinoma of the cervix.

Citing Articles

New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.

Zhang C, Sheng Y, Sun X, Wang Y Cancer Metastasis Rev. 2023; 42(3):891-925.

PMID: 37368179 PMC: 10584725. DOI: 10.1007/s10555-023-10113-2.


Identification of a methylation panel as an alternative triage to detect CIN3+ in hrHPV-positive self-samples from the population-based cervical cancer screening programme.

de Waard J, Bhattacharya A, de Boer M, van Hemel B, Esajas M, Vermeulen K Clin Epigenetics. 2023; 15(1):103.

PMID: 37322534 PMC: 10273737. DOI: 10.1186/s13148-023-01517-6.


Detection of Host Cell Gene/HPV DNA Methylation Markers: A Promising Triage Approach for Cervical Cancer.

Zhang L, Tan W, Yang H, Zhang S, Dai Y Front Oncol. 2022; 12:831949.

PMID: 35402283 PMC: 8990922. DOI: 10.3389/fonc.2022.831949.


Genome-wide host methylation profiling of anal and cervical carcinoma.

Siegel E, Ajidahun A, Berglund A, Guerrero W, Eschrich S, Putney R PLoS One. 2021; 16(12):e0260857.

PMID: 34882728 PMC: 8659695. DOI: 10.1371/journal.pone.0260857.


Identification of potential diagnostic and prognostic biomarkers for LUAD based on TCGA and GEO databases.

Zheng Q, Min S, Zhou Q Biosci Rep. 2021; 41(6).

PMID: 34017995 PMC: 8182989. DOI: 10.1042/BSR20204370.